Akebia Therapeutics Statistics

Total Valuation

AKBA has a market cap or net worth of $332.26 million. The enterprise value is $399.48 million.

Market Cap	332.26M
Enterprise Value	399.48M

Important Dates

The next estimated earnings date is Wednesday, November 6, 2024, before market open.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

AKBA has 210.29 million shares outstanding. The number of shares has increased by 7.22% in one year.

Shares Outstanding	210.29M
Shares Change (YoY)	+7.22%
Shares Change (QoQ)	+2.32%
Owned by Insiders (%)	2.74%
Owned by Institutions (%)	25.79%
Float	190.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.81
Forward PS	1.78
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.29
EV / EBITDA	97.89
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.04

Current Ratio	1.04
Quick Ratio	0.65
Debt / Equity	n/a
Debt / EBITDA	10.38
Debt / FCF	n/a
Interest Coverage	-4.48

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-8.84%
Return on Capital (ROIC)	-26.29%
Revenue Per Employee	$1.04M
Profits Per Employee	-$242,168
Employee Count	167
Asset Turnover	0.74
Inventory Turnover	1.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +89.35% in the last 52 weeks. The beta is 0.76, so AKBA's price volatility has been lower than the market average.

Beta (5Y)	0.76
52-Week Price Change	+89.35%
50-Day Moving Average	1.40
200-Day Moving Average	1.38
Relative Strength Index (RSI)	70.18
Average Volume (20 Days)	1,475,136

Short Selling Information

The latest short interest is 18.80 million, so 8.94% of the outstanding shares have been sold short.

Short Interest	18.80M
Short Previous Month	19.06M
Short % of Shares Out	8.94%
Short % of Float	9.88%
Short Ratio (days to cover)	12.81

Income Statement

In the last 12 months, AKBA had revenue of $174.50 million and -$40.44 million in losses. Loss per share was -$0.21.

Revenue	174.50M
Gross Profit	143.60M
Operating Income	-33.52M
Pretax Income	-40.44M
Net Income	-40.44M
EBITDA	4.08M
EBIT	-33.52M
Loss Per Share	-$0.21

Full Income Statement

Balance Sheet

The company has $39.50 million in cash and $104.62 million in debt, giving a net cash position of -$65.12 million or -$0.31 per share.

Cash & Cash Equivalents	39.50M
Total Debt	104.62M
Net Cash	-65.12M
Net Cash Per Share	-$0.31
Equity (Book Value)	-33.75M
Book Value Per Share	-0.16
Working Capital	4.80M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$38.97 million and capital expenditures -$29,000, giving a free cash flow of -$39.00 million.

Operating Cash Flow	-38.97M
Capital Expenditures	-29,000
Free Cash Flow	-39.00M
FCF Per Share	-$0.19

Full Cash Flow Statement

Margins

Gross margin is 82.29%, with operating and profit margins of -19.21% and -23.18%.

Gross Margin	82.29%
Operating Margin	-19.21%
Pretax Margin	-23.18%
Profit Margin	-23.18%
EBITDA Margin	2.34%
EBIT Margin	-19.21%
FCF Margin	-22.35%

Dividends & Yields

AKBA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.22%
Shareholder Yield	-7.22%
Earnings Yield	-12.10%
FCF Yield	-11.66%

Analyst Forecast

The average price target for AKBA is $5.75, which is 263.92% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.75
Price Target Difference	263.92%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	18.40%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AKBA has an Altman Z-Score of -9.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-9.49
Piotroski F-Score	2